ArticleThe Journal of dermatology2025
Minoxidil Promotes Hair Growth in a Mouse Model of Telogen Effluvium Induced by Lipopolysaccharide.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Telogen effluvium (TE) refers to a transient hair loss condition due to the global and premature transition of scalp hair follicles from the anagen to the telogen phase of the hair cycle leading to excessive hair loss, which is triggered by a variety of physical/emotional stress, including severe infectious diseases. Because of its self-healing nature, attempts to develop remedies for TE have rarely been conducted; still the demand for TE treatment exists as the condition can significantly impair the quality of life of affected individuals. This study aims to establish a mouse model of TE induced by lipopolysaccharide (LPS) and evaluate the therapeutic effects of topical minoxidil (tMXD), an established hair growth-promoting medication. Mice had their dorsal hairs plucked to induce anagen transition and were administered LPS. LPS elicited a condition mimicking a cytokine storm with increases in interleukin-6 levels and neutrophil counts. Accelerated transition of hair follicles into telogen was observed in LPS-treated mice. Intriguingly, tMXD accelerated hair regrowth in LPS-treated mice, resulting in earlier achievement of complete hair regrowth compared to controls. In aggregate, a previously unreported TE mouse model is established, and its use supports the ameliorative effect of tMXD on TE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.